Athira Pharma (NASDAQ:ATHA) Trading Down 1.8% – What’s Next?

Athira Pharma, Inc. (NASDAQ:ATHA) shares dropped 1.8% during mid-day trading on Monday . The stock traded as low as $3.87 and last traded at $3.88. Approximately 3,349 shares were traded during trading, a decline of 85% from the average daily volume of 22,008 shares. The stock had previously closed at $3.95.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ATHA shares. Mizuho set a $4.00 price target on Athira Pharma in a report on Friday, September 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell” and a consensus price target of $4.00.

Athira Pharma Stock Down 1.8%

The stock has a market cap of $15.29 million, a price-to-earnings ratio of -0.40 and a beta of 2.95. The stock’s fifty day moving average is $4.18 and its 200-day moving average is $3.85.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($1.51). As a group, equities research analysts predict that Athira Pharma, Inc. will post -2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Athira Pharma

An institutional investor recently bought a new position in Athira Pharma stock. Focus Partners Wealth acquired a new stake in shares of Athira Pharma, Inc. (NASDAQ:ATHA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 8,415 shares of the company’s stock, valued at approximately $35,000. Focus Partners Wealth owned approximately 0.21% of Athira Pharma at the end of the most recent reporting period. 57.12% of the stock is currently owned by hedge funds and other institutional investors.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.